Clinical trial · Observational
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
NCT05188911CI-TRIAL-00055928unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
By incorporating dual-tracer PET/CT (PSMA and FDG) and ctDNA, we aimed to evaluate lesion heterogeneity and genomic change of mCRPC patients receiving novel hormonal therapy. The relationship between treatment response and different molecular characterization, as well as imaging features would also be evaluated.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Castration-resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma | ALIAS | 0.90 |
| Metastatic Disease | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Abiraterone | Drug | Abiraterone | ALIAS |
| Androgen deprivation therapy | Drug | — | UNRESOLVED |
| Prednisone | Drug | Prednisone | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- mCRPC
- description
- Patients would be treated with 1000mg abiraterone qd. Patients would be treated with 5mg prednisone bid. Patients would get medical or surgical castration.
- interventionNames
- Drug: Abiraterone
- Drug: Prednisone
- Drug: Androgen deprivation therapy
Primary outcomes (2)
- measure
- Lesion heterogeneity on dual-tracer PET/CT
- timeFrame
- 90 days
- measure
- Genomic change
- timeFrame
- 30 days
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: 1. Diagnosed as mCRPC according to EAU-ESTRO-SIOG 2016 and PSA \> 10ng/ml; 2. No previous treatment with novel hormonal therapy; 3. ECOG 0-2; 4. Normal organ function, WBC \>= 3000/mm3 or Neutrophil \>= 1500/mm3; 5. Aged 18 to 85 years old when issuing written informed consent; 6. Life expectancy \> 12 months. 7. Consent and able to carry out follow-up visit and cooperate with all other study procedures. Exclusion Criteria: 1. Severe disease or other medical conditions suggesting a high risk of death within 1 year, which may interfere with follow-up. Decided by investigator; 2. Diagnosed with any other malignant tumor within 3 years before enrollment; 3. Unable to provide necessary follow-up information; 4. Other conditions that are judged as ineligible by the investigator.
References
Publications (1)
- DERIVEDPan J, Wu J, Wang B, Zhu B, Liu X, Gan H, Wei Y, Jin S, Hu X, Wang Q, Song S, Liu C, Ye D, Zhu Y. Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer. Med. 2024 Dec 13;5(12):1475-1484.e3. doi: 10.1016/j.medj.2024.07.020. Epub 2024 Aug 15. PMID 39151419